NewsFeed
Headlines ASRM ESHRE FIGO ACOG Fertility and Sterility PCOS
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Martin Haluzík: The Effects of GLP-1 Receptor Agonists on PCOS
Martin Haluzík/LinkedIn
Nov 29, 2025, 03:42

Martin Haluzík: The Effects of GLP-1 Receptor Agonists on PCOS

Martin Haluzík, Professor of Medicine at Institute for Clinical and Experimental Medicine, shared a post on LinkedIn:

“The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review

Interesting paper just published in Cureus.

  • Polycystic ovarian syndrome (PCOS) is the most common endocrinopathy in reproductive-aged women worldwide; however, treatment modalities often lack cohesion due to its multifactorial pathophysiology. PCOS is suspected of inducing insulin resistance.
  • Research has explored the use of newly developed incretin mimetics as standard therapy for insulin resistance in insulin-dependent tissues associated with PCOS.
  • The aim of this review was to explore the classes of incretin mimetics, such as glucagon-like peptide-1 (GLP-1) receptor agonists or semaglutide, dual agonists of the GLP-1 receptor and gastric inhibitory peptide (GIP) or tirzepatide, and a new triple agonist, or retatrutide (which is currently seeking Food and Drug Administration (FDA) approval), and their suggested benefits as a treatment for PCOS.
  • A literature review was conducted using EBSCO Medline and PubMed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
  • All three classes of incretin mimetics showed significant improvement in weight loss and insulin sensitivity when compared to traditional pharmacological management with metformin and estradiol-progesterone combination pills in patients with PCOS.
  • The added upregulation of GIP in dual-acting and triple-acting agonists, such as tirzepatide and retatrutide, respectively, resulted in greater reductions in weight loss and insulin sensitivity when compared to medications that acted at the GLP-1 receptor alone.
  • Some research demonstrated symptom improvements specific to PCOS presentation, such as dysmenorrhea and the classic dysmorphic ovarian morphology.
  • Further research is warranted to determine the exact mechanism behind how incretin mimetics may improve the hormonal dysregulation in patients with PCOS, as well as how to best use these medications in conjunction with the current standard of care treatments.
  • Very interesting review on an emerging topic
  • The use of antiobesity medications will be very likely expanding in this therapeutic area
  • There are some emerging data on improvement of testosterone levels in men with testosterone deficiency. Perhaps we will see normalization of sex hormones in females as well.
  • As always, we need some good randomized trials.”

Stay updated on all scientific advances in the field of fertility with Fertility News.

Dysmenorrhea endocrine health Endocrinology Endocrinopathy Estradiol-Progesterone FDA Approval Fertility Fertility News Gastric Inhibitory Peptide GIP GIP Upregulation GLP-1 GLP-1 Receptor Agonists Hormonal Disorders Hormonal Dysregulation Incretin Mimetics Insulin Resistance Martin Haluzík Metformin PCOS Polycystic ovarian syndrome PRISMA PRISMA Guidelines Reproductive Endocrinology reproductive health Scoping Review Women’s Health
NewsFeed